Literature DB >> 18086004

Genetics of late-onset Alzheimer's disease: progress and prospect.

Yonghong Li1, Andrew Grupe.   

Abstract

Genetic susceptibility factors for late-onset Alzheimer's disease remain largely elusive, with the exception of apolipoprotein E4 (APOE e4) as the only confirmed genetic risk factor. Numerous other putative risk markers have been proposed, although all suffer inconsistent replication. These results suggest that modest effect sizes are likely to be the norm for non-APOE-related factors. This unsettling situation has been similar to other complex diseases such as diabetes and cardiovascular diseases until very recently, when a spate of new, although weak, genetic markers has been convincingly linked to these conditions. If we assume that multiple weak factors, together with APOE e4, account for the genetic contribution to late-onset Alzheimer's disease risk, it will require the concerted efforts of the greater Alzheimer's genetics community to pool existing genetic resources and/or data to identify novel genetic risk factors that are genuine. Increased confidence in the disease-associated factors will provide the foundation to develop better diagnostic and prognostic tests, select new drug targets and, perhaps, elucidate pharmacogenetic markers that assist in making the best treatment decisions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086004     DOI: 10.2217/14622416.8.12.1747

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  5 in total

1.  Effect of Alzheimer disease genetic risk disclosure on dietary supplement use.

Authors:  Jacqueline A Vernarelli; J Scott Roberts; Susan Hiraki; Clara A Chen; L Adrienne Cupples; Robert C Green
Journal:  Am J Clin Nutr       Date:  2010-03-10       Impact factor: 7.045

2.  Capzb2 PROTEIN EXPRESSION IN THE BRAINS OF PATIENTS DIAGNOSED WITH ALZHEIMER'S DISEASE AND HUNTINGTON'S DISEASE.

Authors:  Charles R Vanderburg; David A Davis; Rachel E Diamond; Patricia F Kao; Ivana Delalle
Journal:  Transl Neurosci       Date:  2010-10-12       Impact factor: 1.757

3.  Increased expression of TrkB and Capzb2 accompanies preserved cognitive status in early Alzheimer disease pathology.

Authors:  Patricia F Kao; Meredith G Banigan; Charles R Vanderburg; Ann C McKee; Peter R Polgar; Sudha Seshadri; Ivana Delalle
Journal:  J Neuropathol Exp Neurol       Date:  2012-07       Impact factor: 3.685

4.  Modulators of cytoskeletal reorganization in CA1 hippocampal neurons show increased expression in patients at mid-stage Alzheimer's disease.

Authors:  Patricia F Kao; David A Davis; Meredith G Banigan; Charles R Vanderburg; Sudha Seshadri; Ivana Delalle
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

5.  Mutation-based structural modification and dynamics study of amyloid beta peptide (1-42): An in-silico-based analysis to cognize the mechanism of aggregation.

Authors:  Pritam Kumar Panda; Abhaysinha Satish Patil; Priyam Patel; Hetalkumar Panchal
Journal:  Genom Data       Date:  2016-01-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.